Novartis achieves breakthrough in Sjögren’s syndrome with successful Phase III trials
Novartis announced positive results from its Phase III trials of ianalumab, demonstrating significant improvement in disease activity for Sjögren’s disease, potentially making it the first targeted treatment for this autoimmune disorder. The trials showed the drug was well tolerated and could soon be submitted for regulatory approval.